• Pipeline
• Clinical Trials

Clinical Trials

CT-322: Phase 1 Safety and Tolerability Study

Our lead Adnectin™ product, CT-322, completed a Phase 1 clinical trial in oncology in the United States in 2008. The trial represented the first time an Adnectin was tested in humans. It was an open label, multi-dose, dose escalation study designed to evaluate safety and tolerability. Interim results from our Phase 1 study were presented at ASCO 2008, and can be viewed by clicking here:
http://www.adnexustx.com/about_pubs.html

To learn more about this trial, please go to the following internet link: http://www.clinicaltrials.gov/ct/show/NCT00374179?order=1Angiocept

CT-322: Phase 2 Recurrent Glioblastoma Multiforme Study

We are enrolling in a multicenter Phase 2 clinical study of CT-322 in eligible patients with recurrent glioblastoma multiforme, the most common and aggressive type of primary brain tumor. To learn more about this trial, which is known as PARADIGM (Phase 2 Assessment of a VEGFR-2 Adnectin In Glioblastoma Multiforme), please click on:
http://www.clinicaltrial.gov/ct2/show/NCT00562419&term=CT322?rank=1

CT-322: Phase 1b / 2 First-Line Glioblastoma Multiforme Study

We have initiated a Phase 1b / 2 clinical study of CT-322 in combination with temozolomide and radiation treatment in patients with newly diagnosed glioblastoma multiforme. To learn more about this trial which is being conducted in multiple sites across the United States, please click on:
http://www.clinicaltrials.gov/ct2/show/NCT00768911?intr=%22CT-322%22&rank=3

To learn more about CT-322 go to: Our Pipeline